JAK Inhibitors in the Management of Atopic Dermatitis | articles
Frontline Forum Part 5: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
December 23rd 2022In part 5 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.
Frontline Forum Part 4: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
December 22nd 2022In part 4 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.
Frontline Forum Part 3: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
December 21st 2022In part 3 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.
Frontline Forum Part 2: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
December 20th 2022In part 2 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.
Frontline Forum Part 1: A Discussion of the Current Treatment Landscape for Atopic Dermatitis
December 19th 2022In part 1 of this Frontline Forum, Raj Chovatiya, MD, PhD; Neal D. Bhatia, MD; Alexandra K. Golant, MD; and Brett King, MD, PhD, discuss the rapidly changing use for JAK inhibitors and other agents for atopic dermatitis.
